



Erratum

Erratum. 9. Pharmacologic Approaches to Glycemic Treatment: *Standards of Care in Diabetes—2024*. *Diabetes Care* 2024;47(Suppl. 1):S158–S178

*American Diabetes Association Professional Practice Committee**

<https://doi.org/10.2337/dc24-er07a>

In the article cited above, the content in Table 9.2 regarding clinical considerations for the class of medications glucagon-like peptide 1 receptor agonists (GLP1-RAs) has been amended to reflect counseling patients about potential for ileus for all medications in this class.

The original content for clinical considerations for GLP1-RAs appeared as follows:
“Counsel patients about potential for ileus (semaglutide SQ)”

The revised content for clinical considerations for GLP1-RAs now reads:
“Counsel patients about potential for ileus”

The online version of Section 9 (<https://doi.org/10.2337/dc24-S009>) has been updated with the revised text.

*A complete list of members of the American Diabetes Association Professional Practice Committee can be found at <https://doi.org/10.2337/dc24-SINT>.